Tech Mahindra Bets On Artificial Intelligence For COVID-19 Drug Research
Tech Mahindra conducts molecular docking studies of 19 FDA (Food and Drug Administration) approved ligands and anti-viral drugs
Makers Lab, the research and development (R&D) arm of Tech Mahindra, a provider of digital transformation, consulting and business reengineering services and solutions, leveraged Artificial Intelligence to conduct research and find potential therapeutic drugs for treatment of COVID-19.
Testimony of a strong synergy among academia, businesses and independent researchers to fight a global pandemic, Tech Mahindra is also collaborating with a renowned bio-scientist for plausible therapeutic drugs and research laboratories for synthesizing and testing these compounds.
CP Gurnani, MD & CEO, Tech Mahindra, said, “The COVID-19 disease continues to disrupt the socio-economic order, impacting lives and livelihood globally. As a leading global digital transformation provider, Tech Mahindra is not only committed to ensure the well-being of our employees, customers and partner ecosystem; but we are also invested in finding a potential cure for COVID-19 by leveraging cutting edge and futuristic technologies like Artificial Intelligence.”
Tech Mahindra’s Makers Lab aims to promote technology innovation and recognise transformative ideas that have a potential to make a difference and create disruptive solutions to solve real world problems. The R&D team has used Molecular docking approach because of high transmission rates of COVID-19.
Nikhil Malhotra, Global Head of Makers Lab, Tech Mahindra, said, “Our objective was to prevent the entry of virus into human host cells such as lung airway epithelial cells. This is important because the high transmission rates of COVID-19 is attributed partly to the high affinity binding and entry of the virus into host cells. Once the virus cannot enter the host cell, it is harmless. Our strategy included finding a GRAS (generally recognized as Safe) agent which can inhibit the virus and we have successfully utilised two areas of research, one is Molecular docking on approved FDA compounds and medicines. Use of Artificial Intelligence helped the research team to evaluate multiple scenarios with different parameters while finding how molecules dock with the main protease.”
The technique, Molecular docking, enables search for therapeutically potent drugs and molecules in real time, to find compounds which can act as inhibitors against a viral protein computationally. Tech Mahindra conducted molecular docking studies across 19 FDA (Food and Drug Administration) approved ligands and anti-viral drugs on the main protease of the virus.
There is more work needed to be done to move the process from molecular docking to actual drug design, testing and drug development at scale. This is just the first step, where computational analysis can reduce the amount of time taken to narrow down the search amongst the vast array of molecules present in the process of finding a cure to COVID-19.
As part of the TechMNxt charter, Tech Mahindra’s Makers Lab is focused on developing future-ready solution by leveraging next gen technologies such as Artificial Intelligence (AI), Machine Learning, Robotics, Internet of Things (IoT), Augmented Reality/ Virtual Reality, 5G – Network of the future. There is a range of business problems that Makers Lab aims to solve in the future to enhance citizen services and customer experiences.